Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 32 Pain, Postoperative 18 Neoplasms 15 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Lung Neoplasms 12 Brain Neoplasms 12 Prostatic Neoplasms 9 Ovarian Neoplasms 8 Colonic Neoplasms 8 Carcinoma, Hepatocellular 8 Stomach Neoplasms 7 Depression 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Pain 6 Head and Neck Neoplasms 6 Thyroid Neoplasms 5 Pancreatic Neoplasms 5 Multiple Myeloma 5 Leiomyoma 5 Agnosia 5 Neoplasm Metastasis 4 Lymphoma 4 Fatigue 4 Delirium 4 Anxiety Disorders 4 Urinary Bladder Neoplasms 3 Thromboembolism 3 Supratentorial Neoplasms 3 Stomatitis 3

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 Cyclophosphamide 135 aldesleukin 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 68 dabrafenib 65 fludarabine phosphate 62 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 Magnetic Resonance Spectroscopy 33 cobimetinib 32 Specimen Handling 31 Introns 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Saline Solution × Clear all

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡